Neurocrine gains on Phase III dyskinesia data

Neurocrine Biosciences Inc. (NASDAQ:NBIX) gained $4.67 (12%) to $43.60 after its NBI-98854 met the primary endpoint in the Phase III

Read the full 202 word article

User Sign In